Associated tags: FDA, Laboratory, AST, Animal Drug Availability Act 1996, East, Microbiology, University Hospitals Cleveland Medical Center, Doctor of Philosophy, Equant, Workflow, Physician, MD, Medical microbiology, McFarland, Blood culture, Pharmaceutical industry
FDA,
Laboratory,
AST,
CEO,
Technology,
Animal Drug Availability Act 1996,
East,
Microbiology,
Department,
University Hospitals Cleveland Medical Center,
Doctor of Philosophy,
Equant,
Workflow,
Physician,
MD,
Medical microbiology,
Time,
McFarland,
Blood culture,
Adoption,
Pharmaceutical industry MENLO PARK, Calif., Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST) announced today the commencement of U.S. pivotal clinical trials for its eQUANTsystem, which will be used to support a submission for FDA clearance.
Key Points:
- MENLO PARK, Calif., Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST) announced today the commencement of U.S. pivotal clinical trials for its eQUANTsystem, which will be used to support a submission for FDA clearance.
- In a recent clinical pilot study Avails demonstrated highly accurate AST results when using the eQUANT McFarland output.
- "Our modular, cost-efficient eQUANT system features a small footprint and straight-forward user interface, making it well suited for widespread adoption from clinical laboratories to community hospitals.
- Avails Medical, Inc., a privately held company, was founded to help fight one of today's biggest global health threats - antibiotic resistance.
MENLO PARK, Calif., June 1, 2021 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today the publication of a new peer-reviewed paper on its eQUANT system and technology in Scientific Reports.
Key Points:
- MENLO PARK, Calif., June 1, 2021 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today the publication of a new peer-reviewed paper on its eQUANT system and technology in Scientific Reports.
- The eQUANT - a novel instrument utilizing electrical biosensors - produces a standardized inoculum equivalent to a 0.5 McFarland directly from positive blood cultures.
- The eQUANT, combined with a rapid, direct from positive blood culture identification technique, can allow the clinical laboratory to begin antimicrobial susceptibility testing using a standardized inoculum approximately 2-3 hours after a blood culture flags positive.
- This has the potential to improve clinical practice by accelerating conventional antimicrobial susceptibility testing and the resulting targeted antibiotic therapy.
eQuant is bridging the gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour.
Key Points:
- eQuant is bridging the gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour.
- The McFarland standard is required in any conventional AST to ensure accurate results.
- It is expected to be the first product in the market to create an automated standardized inoculum directly from positive blood culture.
- Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today's biggest global health threats - antibiotic resistance.
eQuant is bridging the gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour.
Key Points:
- eQuant is bridging the gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour.
- The McFarland standard is required in any conventional AST to ensure accurate results.
- It is expected to be the first product in the market to create an automated standardized inoculum directly from positive blood culture.
- Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today's biggest global health threats - antibiotic resistance.
